| Date | Title | Description |
| 12.05.2026 | Cerevance Completes Enrollment in Pivotal Phase 3 Parkinson’s Disease Trial and Closes Oversubscribed $20 Million Series C to Extend Runway into 2027 | Boston – MAY 12, 2026 – Cerevance, a clinical-stage biopharmaceutical company advancing targeted therapies for neurodegenerative diseases and obesity, today announced completion of patient enrollment in the pivotal Phase 3 ARISE trial evalu... |
| 02.05.2024 | Cerevance Achieves First Milestone in Research Collaboration with MSD | BOSTON, May 02, 2024 (GLOBE NEWSWIRE) -- Cerevance, a company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, announced the achievement of the first milestone in its research collaboration with ... |
| 25.04.2024 | Cerevance Secures $47M to Drive Innovation in CNS Therapeutics | Cerevance, a Boston-based company specializing in precision treatments for central nervous system (CNS) disorders, recently closed a $47 million Series B-1 Extension financing round. The funding, led by Agent Capital, Bioluminescence Ventur... |
| 25.04.2024 | Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline | Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others
Proceeds will advance Cerevance’s first-in-class pre-clinical and clinical programs, including i... |
| 25.04.2024 | Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline | Financing round led by Agent Capital, Bioluminescence, and Double Point Ventures, with participation from new investors MQB Partners and others
Proceeds will advance Cerevance’s first-in-class pre-clinical and clinical programs, including i... |
| 25.04.2024 | Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline | - |
| 25.04.2024 | Cerevance Raises $47M in Series B-1 Extension | Cerevance, a Boston, MA-based company focused on developing precision novel therapeutics for central nervous system (CNS) diseases, raised $47M in Series B-1 Extension.
The round was led by Agent Capital, Bioluminescence Ventures, and Doubl... |
| 25.04.2024 | Cerevance Adds $47M Series B-1 Extension |
BOSTON, MA, Cerevance today announced an initial closing of its Series B-1 Extension financing round that will add $47 million to the $51 million previously raised.
>> Click here for more funding data on Cerevance
>> To export ... |
| 25.04.2024 | Cerevance Adds $47 Million in Series B-1 Extension to Advance Robust Clinical Pipeline | - |
| 13.03.2024 | Cerevance Announces Presentation at Alzheimer’s Research UK Conference | - |
| 13.02.2023 | Cerevance Expands Series B Financing with Additional $51 Million | Proceeds will advance Cerevance’s potential first-in-class programs developed using proprietary NETSseq platform |
| 13.02.2023 | Cerevance Expands Series B Financing with Additional $51M | Cerevance, a Boston, MA-based private, clinical-stage drug discovery and development company, announced an expansion of its Series B funding round with an additional close of $51m, bringing the total Series B financing to $116m.
Backers inc... |
| 13.02.2023 | Cerevance expands financing bringing the total Series B financing to $116 million | - |
| 13.02.2023 | Cerevance Closes $51 M with Series B Expansion |
BOSTON, MA, Cerevance, a private, clinical-stage drug discovery and development company
expands Series B funding round with an additional close of $51 million.
>> Click here for more funding data on Cerevance
>> To export Ce... |
| 13.02.2023 | Cerevance Expands Series B Financing with Additional $51 Million | - |
| 23.01.2023 | Startups measuring the brain that you need to know | Companies are using biomarkers to diagnose and treat mental illness and other neurological disorders
Mental illness is considered the silent pandemic that's been overlooked since the start of COVID. The World Health Organization found the g... |
| 22.07.2020 | Excellent news today from our portfolio company @Cerevance on the expansion of its Series B financing round, adding a further $20 million to the $45 million announced in April. | The additional proceeds will aid in the development of the company’s NETSseq platform which it is using to discover entirely novel drugs and therapeutic targets that could transform the treatment of patients with a range of CNS diseases, in... |
| 21.07.2020 | UPMC Enterprises Joins $65M Series B Financing for Cerevance | BOSTON, July 21, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April. Wi... |
| 21.07.2020 | Foresite Capital Joins $65M Series B Financing for Cerevance | BOSTON, July 21, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April. Wi... |
| 21.07.2020 | Cerevance Expands Series B Financing to $65M | BOSTON, July 21, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has expanded its Series B financing round, adding $20 million to the $45 million that it announced in April. Wi... |
| 17.04.2020 | RDMD raises $14M for rare disease real-world evidence generation | The company said Thursday that it had raised the money in an equity financing round led by PSP Investments, a Canadian pension investment manager. Existing investors KCK Group, Sofinnova Partners, Venrock, T. Rowe Price, TPG’s The Rise Fund... |
| 16.04.2020 | Daily funding roundup - April 15th, 2020 | AI.Reverie raised $5.6M; Atlas AI landed $7M; Nelumbo secured $14M; Perspectum picks up $36M
AI.Reverie: AI.Reverie is a simulation platform that's trying to generate synthetic data to train airport simulation, weapons detection, cashier-le... |
| 14.04.2020 | Cerevance Closes $45 Million Series B Financing - proceeds to fund a diverse pipeline of therapeutics acting on novel targets for brain diseases | Cerevance will use the proceeds of the financing to continue identifying novel therapeutic targets for central nervous system diseases, such as Alzheimer’s disease, by transcriptionally and epigenetically profiling specific neuronal and gli... |
| 14.04.2020 | Touting new way of mining neuro targets, Takeda spinout draws $45M from GV, Bill Gates, Foresite | More than three years after Takeda spun out its top neuroscience team in Cambridge, UK into a transatlantic biotech, GV, Bill Gates and Foresite Capital are chipping in $45 million to power the discovery engine it was found... |
| 14.04.2020 | Cerevance Closes $45M Series B Financing | BOSTON, MA, April 14, 2020 (GLOBE NEWSWIRE) -- Cerevance, a private drug discovery and development company focused on brain diseases, has closed a Series B financing, bringing in $45 million from new investors including GV (formerly Google ... |
| 26.06.2019 | It’s time to find new targets for brain diseases instead of just pursuing old ones | I first learned about drug discovery and development in the mid-1990s when two of my sons were diagnosed with a brutal, untreatable genetic disease called ataxia-telangiectasia (A-T). Children with A‑T struggle with immune deficiency and lu... |
| 29.09.2017 | Pfizer spin-off SpringWorks embraces shelved therapies | Sometimes science is an uncooperative friend that doesn’t play nice with corporate strategies. Promising molecules can bottom out during development – potential oncology or cardiovascular disease drugs may move the needle in those indicatio... |
| 03.05.2017 | Term Sheet — Wednesday, May 3 | GOING GREEN
Hello from New Orleans, where I’m in town for the Collision conference. Yesterday I interviewed two investors about the state of the green-eco-friendly-sustainability-clean tech market: David Mount of Kleiner Perkins’ Green Grow... |
| 03.05.2017 | Cerevance Raises $5m in Equity Funding | Cerevance, a Boston, Massachusetts and Cambridge, UK-based drug discovery startup, raised $5m in equity funding.
The Dementia Discovery Fund, a fund managed by SV Life Sciences, made the investment. In conjunction with the funding, Tetsuyuk... |
| 03.05.2017 | Dementia Discovery Fund to Invest $5 Million in Cerevance | LONDON & BOSTON--(BUSINESS WIRE)--The Dementia Discovery Fund, an innovative global investment fund managed by SV Life Sciences and launched in 2015 to develop disease modifying drugs for dementia, today announced a $5 million investmen... |
| 03.05.2017 | DDF to Invest $5 Million in Cerevance to Seek New Treatments for Dementia | Dementia Discovery Fund to Invest $5 Million in Cerevance to Seek New Treatments for Dementia |
| 06.12.2016 | Cerevance Raises $36M | Cerevance, a Cambridge, MA-based neuroscience company, raised $21.5m in Series A financing.
Founding backers included Takeda Pharmaceutical Company Limited (TOKYO:4502) and Lightstone Ventures, each joining Cerevance’s Board of Directors.
T... |
| 06.12.2016 | Cerevance Raises $36M Funding from Lightstone Ventures | OSAKA, Japan & CAMBRIDGE, Mass.--(BUSINESS WIRE)--Takeda Pharmaceutical Company Limited (TOKYO:4502) and Lightstone Ventures today announced the launch of Cerevance, a neuroscience company focused on discovering and developing novel the... |
| - | RDMD raises $14M for rare disease real-world evidence generation | Despite the ongoing Covid-19 pandemic, many startup companies are continuing to close funding rounds to support their product-development and other efforts. The following is a list of companies that have announced fund raises over the past ... |
| - | Cerevance | “Welcome to the CNS revolution. Cerevance is a revolutionary pharmaceutical company using the proprietary NETSseq platform to develop novel symptomatic and disease modifying therapies for CNS disorders” |
| - | Investors have poured $548 million into neuroscience biotechs this year. Meet the 10 startups that have raised the most cash. | Peter Anastasiou, the CEO of Capsida Biotherapeutics. Capsida Biotherapeutics This story is available exclusively to Insider subscribers. Become an Insider and start reading now.
Neuroscience companies have raised more money from VCs in rec... |
| - | Pfizer spin-off SpringWorks embraces shelved therapies | Pfizer spin-off SpringWorks Therapeutics is carving out a niche repurposing useful molecules from moribund projects. This week, the New York City-based startup brought in $103 million in Series A funding to make that happen.
“SpringsWorks w... |
| - | Cerevance | “Home - Cerevance” |
